GE And Shanghai Pulmonary Hospital Jointly Develop Diagnostics For Pneumoconiosis
This article was originally published in PharmAsia News
Executive SummaryGE China's R&D center recently signed an agreement with Shanghai Pulmonary Hospital to jointly develop CAD techniques which can automatically screen and distinguish diseased and normal human thoracic X-ray images. This technique, which greatly decreases the time and cost for pneumoconiosis checkup, will make examinations accessible to more workers, helping in the prevention and treatment of China's leading occupational disease. Current methods are costly and not very effective, resulting in millions of at-risk local workers unscreened. The two partners will also apply the new technique to the field of digital X-ray and simulation X-ray. (Click here for more - Chinese language)
You may also be interested in...
Brinavess Rejected By Advisory Cmte., Leaving US FDA To Mull Lifting Clinical Hold On Correvio's AFib Drug
Revised North American trade deal touted as enabling Congress to address crisis of high drug prices; requirement for 10 years biologic exclusivity is removed and language to allow incentives for generics added.
The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year.